Contineum Therapeutics Reports Q1 2025 Results: Net Loss Widens to $16M Amid Increased R&D Expenses

Reuters
15 May
Contineum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Q1 2025 Results: Net Loss Widens to $16M Amid Increased R&D Expenses

Contineum Therapeutics Inc. has released its first-quarter 2025 financial results, reporting a net loss of $16.0 million, a significant increase from the $8.4 million net loss in the same quarter of the previous year. This increase is primarily attributed to a substantial rise in research and development expenses, which totaled $13.7 million, reflecting a 76 percent increase from the first quarter of 2024. The rise in expenses is largely due to the advancement of the company's PIPE-791 and PIPE-307 programs, as well as higher employee-related costs. General and administrative expenses also saw an uptick, reaching $4.4 million, up by $2.2 million compared to the first quarter of 2024. This increase was mainly driven by higher stock-based compensation expense and employee-related costs. Contineum Therapeutics remains on track with its key clinical development milestones. The company expects to report topline data from the PIPE-791 Phase 1b PET trial in the second quarter of 2025 and anticipates topline data from the PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in the second half of 2025. The company has completed the chronic toxicity studies for PIPE-791, supporting future Phase 2 trials, and plans to initiate Phase 2 proof-of-concept clinical trials in idiopathic pulmonary fibrosis and progressive multiple sclerosis in the latter half of 2025. With a cash runway projected through 2027, Contineum Therapeutics is focused on executing its clinical development objectives, driven by its vision of developing new therapies for patients with limited treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250514693739) on May 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10